GlassScriptPhysician profile
Scarlett B Ford
NPI 1124362215
$11,804.40
in general payments reported to CMS, 2019-2025
33 companies · $3,398 in 2025
The $3,398 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,259 · 2022: $1,493 · 2023: $1,711 · 2024: $2,944 · 2025: $3,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,052.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,055.92 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Mannkind Corporation | $1,800.04 | 2021-2025 | Afrezza |
| Lilly USA, LLC | $1,313.13 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $681.41 | 2021-2025 | Jardiance, Synjardy |
| Medtronic, INC. | $679.88 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Cequr Corporation | $664.87 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $525.25 | 2021-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $456.22 | 2023-2025 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $447.75 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $432.62 | 2023-2024 | |
| Amgen INC. | $400.66 | 2023-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $329.27 | 2021-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $314.78 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $286.64 | 2025 | Twiist |
| Abbvie INC. | $213.87 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $159.44 | 2023-2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $132.07 | 2021-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $122.61 | 2021 | |
| Zealand Pharma US, INC. | $116.67 | 2022 | |
| Corcept Therapeutics | $109.59 | 2024 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.80 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $81.98 | 2024 | |
| Dexcom, INC. | $81.89 | 2021 | |
| Ibsa Pharma INC. | $55.27 | 2024-2025 | Tirosint, Licart, Flector |
| Ascensia Diabetes Care US INC. | $48.24 | 2023 | |
| Nevro Corp. | $36.95 | 2023-2024 | Senza |
| Astrazeneca Pharmaceuticals LP | $34.80 | 2022-2024 | Lokelma |
| Bigfoot Biomedical INC | $26.16 | 2023 | Unity Diabetes Management System |
| Kyowa Kirin, INC. | $25.12 | 2023 | Crysvita |
| Boston Scientific Corporation | $24.28 | 2025 | Wavewriter Alpha Prime 16 |
| Acella Pharmaceuticals, LLC | $21.53 | 2025 | NP Thyroid 60 |
| Glaxosmithkline, LLC. | $20.51 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scarlett Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.